30 closest matches · ranked by relevance
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
Low Grade Gliomas
Primary: Number of Participants With Late Effects > 3 Months Post RT — 20 Participants
Prostatic Neoplasms
Primary: Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With…
Radiation Dermatitis
Primary: Grade 3 or Higher Adverse Events — 9 Participants
Prostate Cancer
Primary: Percentage of Participants With Physician Reported Rectal Toxicity ≥ Grade 2 During the First 2 Years of Radiation Treatment — 38 percentage of participants — p=0.9138
Prostate Cancer
Primary: Number of Participants With Grade 2 or Greater GU and GI Toxicity — 9; 2; 1; 1 Participants
Breast Cancer
Primary: Success Rate — 65.4 percentage of participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Grade of Xerostomia — 1.14; 1.17 units on a scale
Head and Neck Cancer · Radiation Dermatitis
Primary: Completion Rate of Use of KeraStat Cream — 10; 7 Participants
Lymphedema
Primary: Number of Participants With Acute Toxicity > Grade 2 (Skin Toxicity Grade 3 or Above) Occurring Within 60 Days After First Day of Treatment — 4 Participants
Breast Cancer
Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Head and Neck Neoplasms
Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants
Head and Neck Cancer
Primary: Feasibility of TFRT Planning and Delivery Defined by Number of Participants Starting Radiotherapy Within 15 Days of Simulation — 4 Participants
Cancer, Breast · Inflammation
Primary: Number of Participants Per Cutaneous Toxicity Grade (0, 1, 2, 3, 4) — 60; 11; 0; 0 Participants
Head and Neck Cancer
Primary: Percentage of Participants With Grade 0-1 Observer-rated Dysphagia — 94 percentage of participants
Prostate Cancer
Primary: Number of Participants With Urinary Toxicity Assessed by CTCAE v4.0 — 33 Participants
Prostate Cancer
Primary: Number of Participants With Genitourinary Acute Toxicity — 44; 15; 0; 0 Participants
Breast Cancer
Primary: Incidence of Implant Failure — 8; 17; 34; 41 Number of Participants with Implant Fail
Breast Cancer
Primary: The Number of Participants With a Significant Increase in Perfusion Defects (PD) — 1; 2; 3; 5 participants — p=0.6
Radiodermatitis · Injury, Radiation
Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Xerostomia
Primary: Xerostomia One Month After Completion of Treatment — 5; 7; 1; 6 Participants
Non-rhabdomyosarcoma Soft Tissue Sarcoma · Bone Sarcoma
Primary: Cumulative Incidence (Estimated Percentage of Participants) Who Developed Toxicities Following Radiation Treatment — 17.7 percentage of participants
Breast Cancer
Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins
Non-small Cell Lung Carcinoma · Small Cell Lung Carcinoma
Primary: Number of Participants With Grade 3 or Higher Acute Esophagitis (CTCAE) — 0 Participants
Prostate Cancer
Primary: Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity — 20 participants
Metastatic Epidural Spinal Cord Compression
Primary: Number of Participants Showing Improvement or no Further Progression of Motor Deficits at 1 Month Following Radiotherapy — 68; 69 Participants
Rhabdomyosarcoma
Primary: Cumulative Incidence (Estimated Percent of Participants) With Grade 3 or Higher Toxicity in Follow-up — 10.9 Percentage of patients
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months